Calciotropic Hormones and the Prevalence of Vertebral Fractures in Chinese Postmenopausal Women with Vitamin D Insufficiency: Peking Vertebral Fracture Study

Jiajue, Ruizhi; Jiang, Yan; Qi, Xuan; Wang, Qiuping; Wang, Wenbo; Pei, Yu; Wang, Xiran; Huang, Wei; Zheng, Xin; Ning, Zhiwei; Wang, Ou; Li, Mei; Xing, Xiaoping; Yu, Wei; Xu, Li; Xia, Weibo

doi:10.1007/s00223-019-00531-2

Cited by 5 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Cochrane systematic review and meta-analysis showed that combined VD and calcium supplementation may obtain a decrease in hip fracture and non-VF risk around 15% [126]. In a Chinese study, women with morphometric VFs and hypovitaminosis D had higher PTH levels and more frequently secondary hyperparathyroidism as compared to fracture-free controls [127]. No trial/meta-analysis is available on VD and VFs but it can well be hypothesized that those COVID-19 patients by us observed bearing VFs at hospital admission could have been predisposed to these skeletal events by low levels of VD.…”

Section: Vertebral Fracturesmentioning

confidence: 99%

Hypovitaminosis D and the endocrine phenotype of COVID-19

Giustina

2021

Endocrine

View full text Add to dashboard Cite

Background Vitamin D and its deficiency have recently been suspected to be involved in increased susceptibility and negative outcomes of COVID-19. This assumption was based on the well known immunomodulatory actions of vitamin D and on the consistent finding of low levels of 25 hydroxyvitamin D (25OHD) in hospitalized patients with COVID-19. Moreover, several studies reported a correlation between 25OHD levels and different clinical outcomes of the disease. Aim Aim of the current review was to approach the topic of vitamin D and COVID-19 from a different perspective summarizing the data which led to the evidence of the existence of an endocrine phenotype of COVID-19. Conclusions This review analyzed in the light of the current knowledge the possibility that several endocrine manifestations of COVID-19 could be holistically interpreted in the context of an inadequate vitamin D status. Keywords Vitamin D • Hypocalcemia • Vertebral fractures • Diabetes mellitus • Obesity • COVID-19

show abstract

Section: Vertebral Fracturesmentioning

confidence: 99%

Hypovitaminosis D and the endocrine phenotype of COVID-19

Giustina

2021

Endocrine

View full text Add to dashboard Cite

show abstract

“…Indeed, clinical diagnosis heavily underestimates the dimension of the problem, since most VFs are asymptomatic, pauci-symptomatic, or characterized by self-limited pain ( 56 , 57 ). However, few studies have been able to investigate the effect of V25OH-D levels on prevalence of morphometric VFs ( 58 , 59 ), with discordant results. Moreover, data on D3 supplementation on morphometric VF risk derive only from the control arm of antiosteoporotic drug trials ( 60 , 61 ).…”

Section: Discussionmentioning

confidence: 99%

Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly

Chiloiro,

Frara,

Gagliardi

et al. 2023

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Skeletal fragility is observed in 30% to 60% of acromegaly patients, representing an emerging complication of the disease that increases disability. Despite several studies having investigated the clinical and hormonal prognostic factors for the occurrence of vertebral fractures (VFs) in acromegaly, very few data are available on their prevention/treatment including the effect of vitamin D (VD) supplementation, which has been reported to have a fracture-protective effect in several studies in patients with osteoporosis. Objective We aimed to investigate the role of cholecalciferol (D3) supplementation in the prevention of incident VFs (i-VFs) in acromegaly. Methods A longitudinal, retrospective and multicenter study was performed on 61 acromegaly patients treated and untreated with D3 supplementation. Results Twenty-six patients were treated with D3 supplementation according to clinical guidelines. The median D3 weekly dosage was 8500 IU (interquartile range [IQR]: 3900). The median duration of D3 supplementation was 94 months (IQR: 38). At last follow-up, i-VFs were diagnosed in 14 patients (23%). I-VFs were less prevalent in patients on D3 supplementation (14.3% of cases) compared to patients not treated with D3 (85.7%; P = .02). The final level of serum V25OH-D was significantly lower in patients who developed i-VFs (28.6 ng/mL, IQR: 4.1) compared to patients who did not develop i-VFs (34.2 ng/mL, IQR: 9.6; P = .05). The logistic regression confirmed the protective role of D3 supplementation on the occurrence of i-VFs (odds ratio: 0.16; 95% CI, 0.03-0.79; P = .01). Conclusion It is likely that D3 supplementation could lead to a reduction in i-VFs in acromegaly.

show abstract